July 12, 2023
A Virginia federal judge threw out a suit from pharmaceutical giant AstraZeneca that challenged a rule providing guidelines on whether the Patent Trial and Appeal Board should deny patent reviews due to looming district court trials.
April 06, 2023
The U.S. Patent and Trademark Office has argued that a recent court decision reviving Apple's lawsuit against the office does not support a separate challenge to a rule providing guidelines on whether the Patent Trial and Appeal Board should deny patent reviews due to looming district court trials.
July 25, 2022
AstraZeneca lawyers want a Virginia federal judge to give her take on a memo recently penned by U.S. Patent and Trademark Office Director Kathi Vidal that adjusted how patent board judges decide whether to take on petitions that are attached to patent cases with upcoming trial dates.
April 08, 2022
The Patent Trial and Appeal Board has agreed to review a Seagen Inc. antibody patent after the board previously used its discretion to reject two challenges from Daiichi Sankyo Inc. and AstraZeneca while a Texas federal jury on Friday found Daiichi willfully infringed the patent to the tune of $41.8 million.
February 23, 2022
Pharmaceutical giant AstraZeneca says that the way the U.S. Patent and Trademark Office made the so-called Fintiv rule precedential differs so much from the procedure at other federal agencies that the rule can't be allowed to stand.
August 06, 2021
Pharmaceutical giant AstraZeneca is the latest to say the Patent Trial and Appeal Board's policy of rejecting patent reviews based on district court litigation violates the law, arguing in a new lawsuit that applying the policy to post grant reviews renders those procedures "meaningless."